Tin tức & Cập nhật
Xem bài viết Tiêu hóa
Xem
Chỉ hiển thị Multimedia

COMMIT: Triplet regimen extends PFS in select CRC patients
04 Feb 2026
bởiAudrey Abella
In the phase III COMMIT* trial, a combination of mFOLFOX6 (FFX), atezolizumab, and bevacizumab significantly improves progression-free survival (PFS) in patients with deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC).








